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Abstract 
In this short report, we demonstrate that liposomes bearing the Lewis X trisaccharide on the surface 
(“Awesosomes”) efficiently target human dendritic cells. We chose a glycolipid with Lewis X 
trisaccharide headgroup to facilitate the targeted liposome uptake via the DC-SIGN internalization 
pathway. While no uptake of Awesosomes was detected with wild-type human HEK293 cells, HEK293 
cells transfected with human DC-SIGN internalized Awesosomes extensively. In samples of human 
blood-derived leukocytes, the extent of uptake of Awesosomes correlated with the expression of DC-
SIGN, which is a dendritic cells marker. There was a marked difference in the uptake of Awesosomes and 
plain liposomes by DC-SIGN expressing dendritic cells. There was no difference in uptake of Awesosomes 
and plain liposomes by wt HEK293 cells or macrophages.  These results indicate that Lewis X 
trisaccharide can “sweet-talk” dendritic cells into internalizing a delivery vehicle, and that Awesosomes 
are promising as “magic bullets” for specific delivery of drugs, antigens, or immunostimulatory 
molecules to human dendritic cells without influencing other cell types. 
Introduction  
Dendritic cells (DCs) are the most powerful antigen 
presenting cells. They are extremely potent in priming 
naïve T-cells (and have been therefore designated the 
“nature’s adjuvants” [Steinman, 2007], and in inducing 
cytotoxic immune responses (CTL). Cytotoxic response is 
required for an efficient protection against a number of 
pathogens that evade immune response, and also against 
cancer. Importantly, DCs are capable of cross-
presentation, the induction of a cytotoxic cell response 
against exogenously acquired antigen [Bevan, 1976]. This 
mode of CTLs induction against an exogenous antigen has 
been described only relatively recently and is extremely 
important for developing vaccines against certain 
pathogens including malaria, HIV, and TB [Winau, 2006], 
but also against tumor cells. 
In addition to antigen targeting to DCs, which has already 
been described [Bonifaz, 2004; Sancho, 2009] and shown 
to increase vaccine performance, we believe that also 
targeting of immunostimulatory molecules and other 
adjuvants may be beneficial. Targeted delivery of 
immunostimulants should decrease the likelihood of 
mounting a generalized inflammatory response; current 
adjuvants elicit a generalized inflammatory response, 
often leading to a number of side effects like swelling. 
Thus, our aim was to find a way to target a universal 
delivery vehicle suitable for delivery of both antigens and 
adjuvants to DCs. Liposomes are an ideal vehicle because 
they provide the interior aqueous environment for 
encapsulation of hydrophilic molecules (e.g. protein and 
peptide antigens, or soluble immunostimulatory 
molecules like CpG or poly I:C), and the lipid membrane, 
which can harbor hydrophobic molecules (acyl-modified 
peptides, TLR4 agonists derived from lipid A, etc.).  
We chose to target DC-SIGN receptor, a C-type lectin for 
which the ligand profile has been thoroughly 
characterized and high-affinity glycan ligands have been 
identified [Guo, 2004]. Lewis X trisaccharide has been 
identified as one of the best DC-SIGN ligands.  Esnault et 
al. described the synthesis of highly hydrophic Lewis X 
glycolipids [Esnault, 2001] which bind DC-SIGN. We show 
that POPC liposomes with 0.5mol% of this Lewis X 
compound are efficiently taken up by human blood 
derived dendritic cells. 
Materials and Methods 
Preparation of plain liposomes and Awesosomes 
Lipids were mixed in chloroform and dried under a stream 
of nitrogen. The resulting film was hydrated with 20mM 
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HEPES/130mM NaCl, pH 7.25, vortexed, sonicated, and 
allowed to go through 1 to 5 freeze-thaw cycles before 
extrusion through 100nm polycarbonate membrane at a 
temperature equal or higher than that of the Tm of the 
lipids. 
Transfection of HEK293 cells with DC-SIGN 
HEK293 cells were seeded at a density of ~25000 cells / 
cm2. Next day, they were transfected using the FuGENE 
(Roche) transfection reagent as follows: 1.5g  pcDNA3.1 
containing the human DC-SIGN (a kind gift of Benhur Lee, 
LA) was mixed with 4.5l FuGENE  in 100ul serum-free 
MEM media, and allowed to complex for 10-30’. The 
mixture was then added to the cells in complete media 
(0.1g DNA was enough for 1cm2 cells). The transfected 
cells were then incubated O/N to allow for the expression 
of DC-SIGN. 
Cell imaging and  immunofluorescence 
In order to visualize the uptake of liposomes, 0.05% of 
DiO-C18 or DiI-C18 (Invitrogen) was included in the lipid mix. 
For viewing, the cells were washed extensively with 
PBS/0.2% BSA/0.5% gelatin/2mM EDTA, fixed with 4% PFA 
(DAPI was included when required), and when 
appropriate, blocked with PBS/gelatin and stained with 
FITC-conjugated anti-DC-SIGN antibody (R&D FAB161F, 
used at a recommended dilution). The cells were then 
washed again and finally mounted in mowiol for viewing. 
Liposome internalization assays 
Cells were grown in 96 well plates to confluency. 
Liposomes were added at a concentration of 0.3mM lipid, 
mixed, and incubated as indicated. When the incubation 
period was over, the cells were chilled quickly on ice, 
washed extensively with PBS/gelatin/EDTA, and the 
fluorescence was measured in PBS. 
New synthetic method of Lewis X neolipid 
The Lewisx neolipid 1 used in this study was originally 
synthesized by our group for study of its monolayer 
behaviour [Esnault, 2001].  A more efficient synthetic 
route for this compound has been developed recently in 
our group which was depicted in Scheme 1. 
The known pentasaccharide trichloroacetimidate 2, 
readily obtained by our previous report [Gourier, 2005], 
was condensed with the known alcohol 3 [Esnault, 2001]. 
The reaction was promoted by trimethylsilyl triflate 
(TMSOTf) in dichloromethane in the presence of 
molecular sieve (4Å) at 0°C for 4h to give the protected 
Lewisx neolipid 4 in 68% yield. De-O-acetylation of 
compound 4 by sodium methoxide in methanol and 
dichloromethane at room temperature for 3h provided 
the target product 1 in 98% yield. Both compounds 1 and 
4 were fully characterized by 1H NMR, 13C NMR and Mass 
Spectroscopy analyses. 
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Scheme 1 
Results and Discussion 
DCs express multiple surface receptors that are 
endocytosed upon ligand binding – among others the 
ubiquitous mannose receptor and other C-type lectin 
receptors including some DC-specific receptors like DC-
SIGN. Many of those receptors can be used for the desired 
targeted uptake, and some of them will favor cross-
presentation. It has been shown by conjugating an antigen 
to anti-DEC-205 antibody that it is indeed possible to 
increase the efficiency of vaccination for T cell immunity 
by targeting the antigen to DCs [Bonifaz, 2004]. However, 
our objective was to achieve a “protein-free” targeting, 
and to develop a system that is flexible and easily 
customizable. Using a saccharide structure to target a 
lectin receptor seems to be a reasonable choice. In the 
past, branched oligo-mannose and fucose structures, 
which are common in pathogens, were used both on 
liposomes and emulsions [White, 2006; Yeeprae, 2005; 
Copland, 2003]. The use of such non-specific structures 
was effective in enhancing particle uptake in general 
because these glycans are recognized by a number of 
surface lectin receptors, however, these molecules do not 
provide the desired efficient targeting effect. It is also 
important to keep in mind that in order to achieve the 
desired CTL immunity, the target receptor has to direct 
the cargo into the MHC I pathway, which is not the case 
with the mannose receptor [Sallusto, 1995]. 
We felt that the time is now ripe to revisit the idea of 
modification of liposomal surface with oligosaccharide 
structures while taking an advantage of the recent 
advances in identification and characterization of lectin-
type receptors on the surface of DCs. Our approach is 
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novel in that the oligosaccharide structures that we 
employ are not generic structures targeting a broad range 
of receptors, but are rationally designed to target a 
known, specific receptor (DC-SIGN) on a known type of 
cells (DCs).  According to the excellent study by Guo et al. 
[Guo, 2004], Lewis a and Lewis X trisaccharides are 
efficiently recognized by DC-SIGN while escaping binding 
to the DC-SIGN homologue DC-SIGNR, which is expressed 
on endothelial cells. We chose the glycolipid first 
introduced by Esnault et al. [Esnault, 2001] as the 
targeting signal. This compound has a pentasaccharide 
headgroup composed of the Lewis X trisaccharide  
determinant connected via a lactose group to the lipid 
backbone (1, Scheme 1). Similar approach was reported to 
target model protein antigen, ovalbumin, to DC-SIGN by 
conjugating Lewis X antigen [Wang, 2006; Singh, 2009]. 
The results obtained with Lewis X-targeted antigen are 
highly encouraging.  
In general, the amount of the vaccine components that 
the cells internalize will correlate with their concentration 
at the site of injection and with their 
endocytic/pinocytic/phagocytic activity.  Thus, in order to 
limit the uptake of a vaccine component to DCs, efficient 
targeting signal is needed. Ideally, the vehicle should not 
be readily internalized by any other cells than DCs. 
In order to gain maximum benefit from the targeting 
effect of the Lewis glycolipid (Lx), we were looking for 
liposomes that are internalized poorly, especially by 
macrophages.  Hence we avoided positively charged lipids 
because the liposomes with positive charge are readily 
taken up by all cells and thus the targeting capacity of the 
Lewis glycolipid would be masked. We tested 10 different 
lipid compositions in RAW 264.7 macrophages and mouse 
bmDCs. The compositions were based on our experience 
and available literature, and the uptake was followed by 
measuring fluorescence (Figure 1).  
In order to ensure that the measured fluorescence 
corresponded to endosomal uptake of the liposomes, we 
confirmed the results by microscopy (Supplemental figure 
1). We chose simple POPC liposomes, because the kinetics 
of uptake were similar to transferrin, the total amount 
internalized was relatively low and very evenly distributed 
among the cells, and there were no aggregates. In 
addition, POPC liposomes are stable and non-toxic. Also 
binary mixtures of POPC and cholesterol gave good results 
(Figure 1) but we used POPC for simplicity. However, it is 
clear that the uptake can still be fine-tuned by changing 
the composition. In addition, also the size of the 
liposomes is an important factor – because the idea was 
to target DCs via receptor mediated endocytosis, we used 
liposomes of ~100nm diameter (large unilamellar vesicles, 
LUVs). Considerably larger liposomes could be 
preferentially taken up by phagocytosis. 
Next we tested the targeting effect of POPC liposomes 
with 5 mol% Lx. We used wt HEK293 cells and HEK293 
cells transfected with human DC-SIGN plasmid. The results 
were remarkably unambiguous. Virtually no uptake of 
plain POPC liposomes was observed with either wt or DC-
SIGN transfected HEK293 cells, and the same result was 
obtained with POPC-Lx liposomes (“Awesosomes”) in wt 
HEK293 cells. However, copious amounts of Awesosomes 
were internalized by DC-SIGN expressing HEK293 cells 
(Figure 2). 
 
Figure 1  Uptake of liposomes of different lipid compositions by RAW 
264.7 macrophages.  All liposomes were approximately 120nm in 
diameter. As a reference, we used Alexa488-conjugated transferrin 
(Tf488). The uptake was quantified by measuring fluorescence. 
 
Figure 2 Uptake Awesosomes by wt and huDC-SIGN expressing 
HEK293 cells The 3 panels  on top left, top right, and bottom right show 
one and the same view-field of the wt HEK293 cells that were exposed 
to Awesosomes. The bottom right panel shows HEK293 cells 
transfected with human DC-SIGN that were exposed to Awesosomes 
under identical conditions (incubation time ~30’, 37°C). 
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Finally we tested the uptake by human blood derived DCs. 
DCs were derived by established methods either by 
selecting CD14+ monocytes using magnetic CD14 beads 
and subsequently differentiating into DCs, or by plate 
adherence selection followed by differentiation (IL-4 + 
GM-CSF). We obtained similar results with DCs prepared 
either way. The results were virtually identical to the 
results obtained with HEK293 cells: no uptake of 
Awesosomes was observed with cells that did not stain for 
DC-SIGN, while uptake of Awesosomes by DC-SIGN 
positive cells (ie DCs) was robust (Figure 4). This was 
established by microscopy, and then further validated by 
flow cytometry analysis which quantitatively confirmed 
the correlation of Awesosome internalization with surface 
expression of DC-SIGN (Figure 4, bottom right). 
 
Figure 3 Only cells expressing DC-SIGN internalize Awesosomes     A 
sample of human blood-derived DCs (80-90%) was given Awesosomes 
and subsequently fixed and stained with DAPI (stains all cells, blue) and 
anti-DC-SIGN antibody (stains DCs, green). It is clear that the expression 
of DC-SIGN correlates with the internalization of Awesosomes 
In addition, we investigated how much of the Lx-glycolipid 
needs to be included to provide a sufficient targeting 
effect. We tested  0.05%, 0.1%, 0.5%, 1% and 5% (fractions 
expressed as molar %). No targeting effect was observed 
with 0.05%, and the difference between uptake of plain 
liposomes and liposomes with 0.1% was not convincing. 
However, using 1% appeared to be equally good as 5%, 
and the difference between 0.5% and 1% was only 
marginal as judged by microscopy (data not shown). Thus 
the optimal targeting concentration lies between 0.1 and 
0.5%, which corresponds to approximately 100 to 500 
molecules in the outer leaflet. 
Taken together, we have shown that Lx-POPC 
Awesosomes efficiently target human monocyte-derived 
dendritic cells. The same approach could be possibly used 
to target endocytic lectin-type receptors other than DC-
SIGN. We are sure that this will be a fruitful area of 
research in the future. 
 
Figure 4 Uptake of plain liposomes and Awesosomes by human blood-
derived DCs   Human blood-derived DCs were incubated with plain 
liposomes (top) or Awesosomes (bottom) for ~30’, washed, fixed, and 
stained with DAPI (blue, stains all cells) and anti-DC-SIGN (green, stains 
dendritic cells). The panel on the right the same sample analyzed by 
flow-cytometry; for compensation, single stained and unstained 
controls were used.  
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Supplemental figures 
 
Supplemental figure 1 Uptake of liposomes of different lipid 
compositions by RAW 264.7 macrophages:  Images A (transferrin) – K 
(POPC) show the wells with cells from Figure 1 at the 30’ timepoint. 
 
Supplemental figure 2 Binding of Awesosomes to wt and huDC-SIGN 
transfected cells: Left column – binding of Awesosomes to wt HEK293 
cells; right column – binding of Awesosomes to huDC-SIGN transfected 
HEK293 cells (top – liposome chanel (DiI), bottom – DAPI) 
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